Institute of Mental Health, Peking University, Beijing, China
Stony Brook University, Stony Brook, New York, USA
IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy
Department of Psychology, University of Cagliari, Italy
Center for Public Mental Health, Gösing am Wagram, Austria
National Institute of Psychiatry, Mexico City, Mexico
University Hospital Gasthuisberg, Leuven, Belgium
Netherlands Institute of Mental Health and Addiction, Utrecht, Netherlands
Department of Psychiatry, University College Hospital, Ibadan, Nigeria
Department of Psychiatry and Clinical Psychology, Saint George Hospital University Medical Center, Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University Medical School, and the Institute for Development, Research, Advocacy and Applied Care (IDRAAC), Beirut, Lebanon
Department of Psychiatry, The Chinese University of Hong Kong, HKSAR, Peoples Republic of China
INSERM U 705, CNRS UMR 7157, University Paris Diderot, Hôpital Lariboisière Fernand Widal, Assistance Publique Hôpitaux de Paris, France
Clinic of Psychiatry, University of Leipzig, Germany
Colegio Mayor de Cundinamarca University, Bogata, Colombia
MRC Anxiety Disorders Research Unit, Department of Psychiatry, University of Stellenbosch, South Africa
Health Services Research Unit, Institut Municipal dInvestigacio Medica (IMIM), CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA
Correspondence: Ronald C. Kessler, Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, Massachusetts 02115, USA. Email: kessler{at}hcp.med.harvard.edu
R.C.K has been a consultant for GlaxoSmithKline, Kaiser Permanente, Pfizer Inc, Sanofi-Aventis, Shire Pharmaceuticals and Wyeth-Ayerst. He has served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst, and has had research support for his epidemiological studies from Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Pharmaceuticals Inc, Pfizer Inc and Sanofi-Aventis.
Background
Little is known about the cross-national population prevalence or correlates of personality disorders.
Aims
To estimate prevalence and correlates of DSM–IV personality disorder clusters in the World Health Organization World Mental Health (WMH) Surveys.
Method
International Personality Disorder Examination (IPDE) screening questions in 13 countries (n = 21 162) were calibrated to masked IPDE clinical diagnoses. Prevalence and correlates were estimated using multiple imputation.
Results
Prevalence estimates are 6.1% (s.e. = 0.3) for any personality disorder and 3.6% (s.e. = 0.3), 1.5% (s.e. = 0.1) and 2.7% (s.e. = 0.2) for Clusters A, B and C respectively. Personality disorders are significantly elevated among males, the previously married (Cluster C), unemployed (Cluster C), the young (Clusters A and B) and the poorly educated. Personality disorders are highly comorbid with Axis I disorders. Impairments associated with personality disorders are only partially explained by comorbidity.
Conclusions
Personality disorders are relatively common disorders that often co-occur with Axis I disorders and are associated with significant role impairments beyond those due to comorbidity.